Abstract
Background
In traditional medicine of Southeast Asian countries, Baeckea frutescens L. (family Myrtaceae) has a long history of use. Numerous research projects have shown that this plant contains metabolites with remarkable medicinal value. No review document, to date, has given an insight into the role of B frutescens constituents in pharmacological development.
Objective
The current review briefly offers crucial information on the phytochemistry, biosynthesis, synthesis, and pharmacology of B frutescens.
Methods
B frutescens is the most meaningful keyword to search for literature data. It was used either on its own or in combination with other keywords. References have been gathered from various resources such as Google Scholar, SciFinder, and PubMed. More than 50 electronic references were collected from the 1960s.
Results
Approximately 130 metabolites have been isolated and structurally determined from this medicinal plant. They included phloroglucinols, phloroglucinol-based meroterpenoids, sesquiterpenoids, triterpenoids, flavonoids, chromones, 5-membered ring compounds, and others. B frutescens fresh tissues were thought to be a rich resource of essential oils. Tasmanone is a precursor in the biosynthesis of various B frutescens compounds, while phloroglucinol derivatives can be seen as initial compounds in the synthetic procedures of various B frutescens molecules. B frutescens plant extracts and compounds isolated from them possess a variety of pharmacological properties, such as cytotoxic, antimicrobial, anti-inflammatory, antioxidant, antirheumatoid, skin protective, and mosquito larvicidal activities.
Conclusion
More experimental reports on phytochemistry and pharmacology are required. In vivo pharmacological studies on the mechanisms of action of the active compounds are urgently required since most of the results obtained so far have been from in vitro assays.
Introduction
Baeckea frutescens L. is a member of the family Myrtaceae and is indigenous to Australia, New Guinea, and eastern Southeast Asia. 1 It is a shrub with arched branches, linear leaves, and 7-13 stamens on each of its white flowers. B frutescens, also known as “Jungrahab,” is an Indonesian folk medicine. 2 Its aerial parts are employed to treat influenza, malaria, fever, headache, dysentery, and abdominal pain. 2 The leaves of this plant are recommended as a remedy for headache, rheumatism, and fever. 3 The leaf decoction was used in Malaysia for diuretic and emmenagogue features. 4 In China, the leaves have been applied as a refreshing herbal tea to cure fever and sunstroke, and the dried leaves could be a febrifuge. 4 The roots of this plant, known as “Pu Lao Zhong,” have good effects in treating rheumatism and snake bites.5,6 B frutescens is used as a daily health tea with the well-known name of “Gang Song Cha.” 7
By chromatographic procedures and liquid chromatography-mass spectrometry (LC-MS) analysis, diverse classes of phytochemicals have been detected. Along with other classes, phloroglucinols, flavonoids, and chromones are likely to be the main types of B frutescens secondary metabolites.5–14 B frutescens essential oils are dominated by terpenoids.15,16 The plant extracts, fractions, and their isolates are now potential agents for drug development since they possess pivotal pharmacological properties, such as cytotoxic, antimicrobial, and anti-inflammatory activities.13,17,18 As an example, frutescone O, at 0.2-0.8 µM, suppressed lipopolysaccharide (LPS)-stimulated RAW264.7 cells by blocking TLR4-mediated mitogen-activated protein kinase (MAPK)/nuclear factor kappa B (NF-κB) signaling pathways and inhibiting MyD88 and iNOS expressions. 19
Although there are plenty of experimental reports, no review article has been recorded until now. For the first time, we review several important aspects of this plant, including phytochemical separations, essential oil identifications, biosynthetic and synthetic pathways, and, especially, the applications of chemical constituents in biomedical examinations.
Phytochemistry
In this section, the outcomes of phytochemical investigations of B frutescens are based on the use of column chromatography (CC) to isolate purified compounds and LC-MS analysis to detect compounds in plant extracts. A list of isolates is summarized in Table 1 and Figures 1 to 3, including phloroglucinols

Phloroglucinols, phloroglucinol-based meroterpenoids, sesquiterpenes, and triterpenoids from Baeckea frutescens.

Flavonoids from Baeckea frutescens.

Chromones, 5-membered ring compounds, and others from Baeckea frutescens.
Chemical Constituents of Baeckea frutescens.
No name.
Abbreviations: CC, column chromatography; LC-MS, liquid chromatography-mass spectrometry.
Phloroglucinols, Phloroglucinol-Based Meroterpenoids, Sesquiterpenoids, and Triterpenoids
Phloroglucinols
The hybrid-type phloroglucinol-based meroterpenoids
Four sesquiterpenoids
Flavonoids
Flavonoids are low-molecular-weight phenolic compounds that are found in a variety of higher plants.35–37 As shown in Table 1 and Figure 2, flavonoids derived from B frutescens can be divided into flavones
Regarding flavones, 13 new derivatives, baeckeins A-M (
In the search for bioactive compounds from natural resources, 3 new cytotoxic flavanones, BF-4 (
Chromones, 5-Membered Ring Compounds, and Others
Chromones, a subclass of flavonoids, are also present in B frutescens. A list of 19 metabolites (
Phytochemical studies on B frutescens further identified the presence of 5-membered ring compounds
Essential Oils
Essential oils are made up of lipophilic and extremely volatile secondary plant metabolites that are physically separable from other plant parts and have a mass below a molecular weight of 300. 38 Hydrodistillation extraction (HE) is likely to be the best extraction approach to obtain a high yield of essential oil.39,40 The major compounds (≥5.0%) of the essential oil of B frutescens, analyzed by gas chromatography-mass spectrometry (GC-MS), are listed in Table 2.
The Main Compounds in Baeckea frutescens Essential Oils.
The leaf oil, collected from Hatinh, Vietnam, was dominated by α-humulene (19.2%), α-caryophyllene (17.3%), baeckeol (13.8%), α-thujene (8.8%), linalool (5.6%), and 1,8-cineole (5.4%), whereas the sample from Danang, Vietnam, yielded β-pinene (19.0%), γ-terpinene (11.7%), α-pinene (11.1%), 1,8-cineole (10.1%), α-humulene (9.9%), and (E)-caryophyllene (7.1%).15,16 In another report, the compounds present in the highest amount in the leaf and stem oils collected from Hue, Hanoi, and Quangbinh, Vietnam, were p-cymene (22.2%), β-pinene (23.3%), and tasmanone (24.3%), respectively. 41 By means of GC-MS analysis, 2 pinene isomers were the best representatives for the leaf oils of Sabah, Kepong, and Selangor, Malaysia, but the leaf oil obtained from Terengganu, Malaysia, contained γ-terpinene (34.1%) and others. 4 β-Caryophyllene (28.05%), α-caryophyllene (24.02%), δ-cadinene (6.29%), eucalyptol (5.46%), and β-pinene (5.21%) were characteristic compounds in the leaf oil of a Chinese sample (Table 2).
Biosynthesis and Synthesis
Biosynthesis
Information on the biosynthesis of B frutescens metabolites is now available in the literature and is focused on meroterpenoids. As shown in Figure 4, phloroglucinol-based meroterpenoids baeckfrutones A-L (

Biosynthetic pathway of baeckfrutones A-L (
Along with the isolation of frutescones A-G (

Biosynthetic pathway of frutescones A-G (
Synthesis
The synthetic procedure for baeckenone B (

Synthetic pathway of phloroglucinol
In 2003, Gray et al
44
demonstrated synthetic steps of 5-hydroxy-7-methoxy-2-isopropylchromone (

Synthetic pathway of chromones
Pharmacology
Cytotoxicity
BF-1 (
Baeckenone F (
Pharmacological Activities of Isolated Compounds and Plant Extracts from Baeckea frutescens.
A549, lung cancer cells; Caco-2 and HCT116, colon cancer cells; COX, cyclooxygenase; DPPH, 2,2-diphenyl-1-picrylhydrazyl; DU145, prostate cancer cells; EC50, half maximal effective concentration; ES-UME, enzymatic surfactant-ultrasonic microwave extraction; HE, hydrodistillation extraction; IZ, inhibitory zone; LC50, half lethal concentration; LC90, 90% lethal concentration; LPS, lipopolysaccharide; L-1210, leukemia cells; LDL, low-density lipoprotein; MCF-7 and MDA-MB-231, breast cancer cells; MAPK, mitogen-activated protein kinase; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; MALP-2, macrophage-activating lipopeptide-2; NO, nitric oxide; NF-κB, nuclear factor kappa B; PSN-1, pancreatic cancer cells; SiHa, cervical cancer cells.
Baeckfrutones B-L (
Cytotoxicity of the n-hexane leaf extract against A549 and NCI-H1299 cancer cells was associated with IC50 values of 56.24 and 26.7 µg/mL, respectively, but the EtOAc, MeOH, and water extracts were either weak or inactive (IC50 > 100 µg/mL). 46 From Table 3, n-hexane, EtOH, and water extracts of the leaf exhibited cytotoxicity against MCF-7 cancer cells (IC50 10-124 µg/mL), but only the n-hexane extract showed activity against MDA-MB-231 (IC50 80 µg/mL). 45 The rich flavonoid fraction remarkably controlled the proliferation of SiHa cancer cells (IC50 110.8 µg/mL, 27.54% apoptosis rate). 47
Antimicrobial and Mosquito Larvicidal Activities
Baeckenone B (
The EtOH and water extracts of B frutescens leaf were active against both Escherichia coli and Salmonella thypi with MIC values of less than 50 µg/mL. 48 At 50 and 100 mg/mL, the EtOH leaf extract also suppressed methicillin-resistant Staphylococcus aureus (MRSA) with inhibitory zone (IZ) values of 8.5-14.5 mm (Table 3). 49 Similarly, at 10 and 20 mg/mL, the MeOH leaf extract was responsible for the inhibition of Streptococcus mutans with IZ values of 13 and 14 mm, respectively. 50
B frutescens leaf oil controlled the growth of Pseudopestalotiopsis camelliae, Colletotrichum gloeosporioides, Enterococcus faecalis, and Candida albicans, with MIC values of 5.11, 4.79, 64, and 16 µg/mL, respectively.16,42 In another approach, the leaf oils extracted by HE and enzymatic surfactant-ultrasonic microwave extraction (ES-UME) exhibited the same antimicrobial activity against C albicans (MIC 1.25%), S aureus, E coli, and B subtilis (MIC 0.625%), Pseudomonas aeruginosa, and Propionibacterium acnes (MIC 0.3125%). 51
Besides antimicrobial activity, B frutescens leaf oil showed 24- and 48-h LC50 values of 15.31-81.72 µg/mL and LC90 values of 34.69-116.6 µg/mL against Aedes aegypti, Aedes albopictus, and Culex quinquefasciatus. 16
Anti-inflammatory Activity
Compound BF2 (

Anti-inflammatory mechanism of compound
In an anti-inflammatory assay against nitric oxide (NO) production in LPS-stimulated RAW264.7 cells, the IC50 values of baefrutones A-D, N, and S (
The flavones baeckeins F-I (
As shown in Table 3, flavones
Antioxidant Activity
Baeckeins J (
Flavones baeckeins A-E (
Two new flavones
The EtOH and water extracts of B frutescens leaf were also the subjects of a DPPH assay, producing respective IC50 values of 41.96 and 93.30 µg/mL, in comparison with that of the standard gallic acid (IC50 3.81 µg/mL). 48 The n-hexane, MeOH, EtOAc, and water extracts of B frutescens leaf showed antioxidative activity in the DPPH radical scavenging, ferric reducing power, and metal chelating models (Table 3). 46 In particular, the water extract (EC50 0.039 mg/mL) was better than the standard EDTA (EC50 0.042 mg/mL) in the metal chelating assay. 46
Besides antimicrobial activity, the HE and ES-UME leaf oils generated IC50 values of 15.9 and 14.0 µg/mL, respectively, in a DPPH antioxidative assay when α-tocopherol was used as a positive control (IC50 0.12 µg/mL). 51 B frutescens leaf oil was also demonstrated as a potential agent in other antioxidative models, in which it possessed ferric reducing power, metal chelating, and β-carotene bleaching, with EC50 values of 0.29-1.39 µg/mL. 53
Antirheumatoid Arthritis and Skin Protective Activities
BF-2 (
The EtOH leaf extract increased the proliferation and migration of keratinocytes and fibroblast BJ cells. In detail, HaCaT's proliferation was increased by 14% and 24% at 6.25 and 3.125 µg/mL, respectively, after 48 h treatment, and BJ's proliferation was increased by 36% and 51% at 25 and 12.5 µg/mL, respectively, after 24 h treatment. 29
Conclusion and Perspective
For the first time, the current review provides full information on the phytochemistry, biosynthesis, synthesis, and pharmacology of B frutescens constituents. Phytochemical studies of B frutescens tissues have led to the isolation and structural determination of 128 secondary metabolites, including 14 phloroglucinols, 47 phloroglucinol-based meroterpenoids, 4 sesquiterpenoids, 3 triterpenoids, 34 flavonoids, 19 chromones, 5 5-membered ring compounds, 1 mono-phenol, and 1 phytosterol. B frutescens is also rich in essential oils, in which monoterpenes, monoterpenoids, sesquiterpenes, and sesquiterpenoids were the main chemical classes. Generally, tasmanone acted as a precursor in biosynthesis, whereas the previous reports dealt with the use of phloroglucinol derivatives in the synthetic procedures of B frutescens molecules. Crude plant extracts, fractions, and the isolates of B frutescens possess a variety of pharmacological activities, such as cytotoxic, antimicrobial, anti-inflammatory, antioxidative, antirheumatoid, skin protective, and mosquito larvicidal activities.
However, further chemical examination is necessary. Some compounds contain stereogenic centers pending the assignment of the absolute configuration, and a good number of compounds have been described as racemic mixtures, which is not common in the biogenesis of natural products. Hence, structural elucidation studies are welcome. There is also a lack of in vitro and in vivo studies of the pharmacological mechanisms of action since most of the data obtained so far have been the result of initial screenings. Many isolated metabolites, especially the major potential compounds, have not yet received attention in pharmacological examinations. Last but not least, structure–activity relationship studies are required, as well as virtual docking calculations.
Footnotes
Authors’ Contributions
DTLH: formal analysis and revision; DXD: collection and formal analysis; and NTS: designated and wrote the manuscript.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
